NYXH Nyxoah
Company Analysis
Latest News
🟢 Nyxoah is trading 5.5% up today with no identified company-specific catalyst
Nyxoah is trading at $0.87, 5.54% up; no new company-specific announcement explaining the October 23 move was identified. - The latest company news was its...
🟢 Nyxoah is trading 7% up in pre-market
Nyxoah is trading at $0.88, up 6.96%, with no clear company-specific news identified to explain the October 23 pre-market rise. - On October 19, Nyxoah...
🔴 Nyxoah is trading 9.89% down in pre-market after cutting its 2026 revenue outlook
Nyxoah is trading 9.89% down at $0.74 in pre-market on October 23 after lowering its 2026 revenue outlook. - On October 19, it cut full-year revenue guidance...
🔴 Nyxoah is trading 10.39% down today after cutting its 2026 revenue outlook
Nyxoah is trading at $0.80 (-10.39%) on October 22, 2026, with its reduced 2026 revenue outlook the clearest company-specific explanation for the decline. -...
🔴 Nyxoah is trading 10% down today after lowering its 2026 revenue outlook
Nyxoah is trading at $0.81, down 9.70%, with its October 19 cut to 2026 revenue guidance remaining the clearest company-specific explanation for the decline. -...
🔴 Nyxoah is trading 27.39% down in pre-market after cutting 2026 revenue outlook
Nyxoah is trading at $0.65, down 27.39%, after cutting its 2026 revenue outlook on October 19. - The company now expects 2026 revenue of €33–35 million, versus...
🔴 Nyxoah is trading 5% down today after cutting 2026 revenue guidance
Nyxoah is trading at $0.89, down 5.31%, after lowering its 2026 revenue guidance. - On October 19, it cut the forecast to €33–35 million from €36–40...
🔴 Nyxoah is trading 5.8% down in pre-market after lowering 2026 revenue guidance
Nyxoah is trading 5.8% down at $0.90 in pre-market on October 20 after cutting 2026 revenue guidance to €33–35 million from €36–40 million. - Preliminary Q3...
🔴 Nyxoah is trading 15.32% down today after cutting 2026 revenue guidance
Nyxoah is trading 15.32% lower at $0.94 after cutting its 2026 revenue outlook. - On October 19, 2026, it forecast full-year revenue of €33–35 million, down...
Nyxoah Cuts Its Revenue Outlook While Burning Cash at $20 Million a Quarter — Can This Sleep Apnea Startup Survive Long Enough to Scale?
Shares of Nyxoah plunged 14.8% to $0.95 in pre-market trading after the Belgian medtech company slashed its 2026 revenue guidance to €33–35 million from €36–40...
🔴 Nyxoah is trading 14.82% down in pre-market after lowering its 2026 revenue outlook
Nyxoah is trading at $0.95, down 14.82%, after lowering its 2026 revenue outlook. - In its October 19 preliminary Q3 update, Nyxoah cut its 2026 revenue...
🔴 Nyxoah is trading 8.1% down in pre-market
Nyxoah is trading 8.1% lower at $1.02 pre-market; the catalyst is unclear. - No new company-specific announcement surfaced in the search for the October 19...
🔴 Nyxoah is trading 5% down today with no clear catalyst identified
Nyxoah is trading 5.03% down at $1.13 on October 16, with no clear catalyst identified. - Nyxoah closed at $1.19 on October 15, down 4.80%. - A proposed $50...
🔴 Nyxoah is trading 6% down today as oil and Treasury yields rise
Nyxoah is trading 5.99% down at $1.33 on October 8, 2026, amid broad risk-off pressure. - No same-day company announcement explaining the decline surfaced in...
🟢 Nyxoah is trading 5% up with no confirmed catalyst
Nyxoah is trading at $1.43, up 5.15%, on October 5, with its specific driver unconfirmed. - Nyxoah’s recent CEO appointment took effect October 1; that...
🟢 Nyxoah is trading 11.28% up in pre-market with no confirmed company-specific catalyst
Nyxoah is trading at $1.48, up 11.28%, with no fresh company-specific announcement identified to explain its October 2 pre-market rise. - Nyxoah’s previously...
🔴 Nyxoah is trading 10.1% down
Nyxoah is trading at $1.43, down -10.06%, with no confirmed company-specific catalyst identified for the September 29 decline. - Nyxoah announced Liam Kelly’s...
🔴 Nyxoah is trading 6.2% down; reason remains unclear
Nyxoah is trading at $1.49, down 6.21%, with no confirmed catalyst identified for the September 29 decline. - Nyxoah announced Liam Kelly’s appointment as CEO...
🔴 Nyxoah is trading 5% down in pre-market with no confirmed catalyst
Nyxoah is trading 5.03% lower at $1.51 in pre-market; no new company-specific catalyst has been identified. - Nyxoah announced Liam Kelly’s appointment as CEO...
Nyxoah Names Liam Kelly CEO to Drive U.S. Growth After Genio Approval
Nyxoah named Liam Kelly its new chief executive officer, effective October 1, 2026. Kelly will succeed Olivier Taelman as the medical technology company steps...